• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Rockwell Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/29/25 4:32:29 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    false 0001041024 0001041024 2025-09-23 2025-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

     

     

    Date of Report (Date of earliest event reported): September 23, 2025

     

    Rockwell Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 000-23661 38-3317208
    (State or other jurisdiction
    of incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)

     

    30142 S. Wixom Road, Wixom, Michigan 48393

    (Address of principal executive offices, including zip code)

     

    (248) 960-9009

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class  Trading  Symbol  Name of Each exchange on which
    registered
    Common Stock, par value $0.0001  RMTI  Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of ther chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of ther chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On September 23, 2025, the Rockwell Medical, Inc. (the “Company”) Board of Directors appointed Heather Hunter as the Company’s Senior Vice President and Chief Operating Officer effective immediately.

     

    Ms. Hunter, age 46, most recently served as the Company’s Senior Vice President and Chief Corporate Affairs Officer since August 2022 and an independent consultant from July 2022 through August 2022. Prior to joining the Company, Ms. Hunter served as Vice President, Communications and Corporate Affairs at Venatorx Pharmaceuticals, a private, venture-backed, pre-commercial pharmaceutical company focused on antibacterial and antiviral drug research and development, from January 2018 to August 2022. Prior to that, Ms. Hunter served in positions of increasing responsibility at Safeguard Scientifics (NYSE:SFE), a small-cap venture capital firm that invested in early- and growth-stage healthcare and technology companies, most recently as Vice President, Marketing and Communications, from October 2006 to January 2018, and W.P. Carey (NYSE:WPC), most recently as Vice President, Corporate Communications, from September 2000 to October 2006. Ms. Hunter currently serves as an Advisory Board member of Journal My Health, a digital health platform focused on patients with chronic conditions, and is a Managing Director at Golden Seeds, an angel investment firm that invests in women-led and women-founded companies. Ms. Hunter graduated with a B.A. in History from Yale University.

     

    On August 31, 2022, in connection with Ms. Hunter’s commencement of employment, the Company entered into an employment agreement with Ms. Hunter (as amended on May 20, 2025, the “Employment Agreement”). The Employment Agreement provides that Ms. Hunter will serve as an at-will employee. Ms. Hunter receives an annualized base salary of $323,574 (subject to adjustment), is eligible to earn year-end performance bonuses with a target bonus opportunity of 45% of her base salary, and is eligible to participate in the employee benefit plans and programs generally available to the Company’s similarly situated senior executives. Ms. Hunter is also eligible to receive annual long-term incentive grants consistent with similar practices for the Company’s senior executives, awarded at the discretion of the Compensation Committee of the Board. In connection with her commencement of employment, she received an initial equity grant comprised of a time-based option to purchase up to 60,000 shares of the Company’s common stock that vests in equal installments on each of the first four anniversaries of August 29, 2022 (the “Initial Time-Based Options”). The Initial Time-Based Options were issued outside of the Company’s stockholder-approved Amended and Restated 2018 Long-Term Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

     

    Under the Employment Agreement, upon a termination of Ms. Hunter’s employment due to death or Disability, any equity awards held by Ms. Hunter subject to time-based vesting conditions (the “Time-Based Awards”) will accelerate and become fully vested. All stock options held by Ms. Hunter that are exercisable as of the date of such termination, including any stock options that accelerate in connection with such termination, will remain exercisable until the earlier of one year following such termination and the expiration date of the stock options. Under the Employment Agreement, upon a termination of Ms. Hunter’s employment by the Company without Cause or by Ms. Hunter for Good Reason, (i) Ms. Hunter will be entitled to receive, subject to her execution and non-revocation of a separation agreement and release of claims in favor of the Company and compliance with certain restrictive covenants, (A) an amount equal to her base salary then in effect, payable in equal installments for a one-year period, and (B) reimbursement of COBRA coverage for up to one year (or, if sooner, until she receives substantially similar coverage from another employer), and (ii) (A) the Time-Based Awards will continue to vest for a period of one year and (B) all stock options held by Ms. Hunter that are exercisable as of the date of such termination and all stock options that become exercisable over the one-year period following such termination will remain exercisable until the earlier of one year following such termination and the expiration date of the stock options.

     

    Under the Employment Agreement, in the event of a Change of Control, upon a termination of Ms. Hunter’s employment by the Company without Cause or by Ms. Hunter for Good Reason during the Effective Period, subject to her compliance with certain restrictive covenants, (i) Ms. Hunter will be entitled to receive (A) an amount equal to the sum of (1) 1 times her base salary then in effect plus (2) a prorated portion of her annual target bonus, and (B) reimbursement of COBRA coverage for up to one year (or, if sooner, until she receives substantially similar coverage from another employer or is no longer eligible for COBRA coverage) and (ii) (A) any Time-Based Awards will accelerate and become fully vested and (B) all stock options held by Ms. Hunter that are exercisable as of the date of such termination, including any stock options that accelerate in connection with such termination, will remain exercisable until the expiration date of the stock options.

     

     

     

     

    In connection with the Employment Agreement, Ms. Hunter also entered into the Company’s form of Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement.

     

    Capitalized terms used herein, but not defined, shall have the meanings given to them in the Employment Agreement. The foregoing summary of the Employment Agreement does not purport to be a complete description of the Employment Agreement and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.Description
      
    10.1Employment Agreement, dated as of August 31, 2022, as amended, between the Company and Heather Hunter.
      
    104Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused ther report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ROCKWELL MEDICAL, INC.
         
    Date: September 29, 2025 By:  /s/ Mark Strobeck
        Mark Strobeck
        Chief Executive Officer

     

     

     

    Get the next $RMTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SVP and CCO Chole Timothy sold $2,352 worth of shares (2,868 units at $0.82), decreasing direct ownership by 2% to 128,167 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:28:08 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President and CEO Strobeck Mark sold $5,679 worth of shares (6,926 units at $0.82), decreasing direct ownership by 2% to 337,752 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:26:18 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SVP and CFO Neri Jesse sold $727 worth of shares (886 units at $0.82), decreasing direct ownership by 0.69% to 126,614 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:24:06 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    SEC Filings

    View All

    Rockwell Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    9/29/25 4:32:29 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rockwell Medical Inc.

    S-8 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    8/14/25 4:11:24 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rockwell Medical Inc.

    10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    8/14/25 7:05:59 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rockwell Medical Promotes Heather Hunter to Chief Operating Officer

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Heather Hunter was promoted to Chief Operating Officer, and will continue to report to the Company's President and CEO, Dr. Mark Strobeck. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930533412/en/Heather Hunter - Chief Operating Officer at Rockwell Medical, Inc. Ms. Hunter joined Rockwell Medical as SVP, Chief Corporate Affairs Officer in August 2022 to revitalize the Company's investor relations, co

    9/30/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces Second Quarter 2025 Results

    Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

    8/14/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Resu

    7/17/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

    Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

    11/14/24 7:56:29 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

    1/18/22 10:00:06 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

    9/7/21 6:17:47 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/15/25 2:02:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

    Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

    10/17/23 6:00:00 AM ET
    $BDN
    $RMTI
    $RCOR
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

    WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

    6/24/22 8:56:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Financials

    Live finance-specific insights

    View All

    Rockwell Medical Announces Second Quarter 2025 Results

    Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

    8/14/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Resu

    7/17/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces First Quarter 2025 Results

    Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

    5/12/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    11/14/24 5:17:40 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    2/14/24 2:31:02 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

    SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    9/6/23 4:49:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care